← Insulin × cardiovascular events

TrialDiabetologia2011

Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.

L G Mellbin et al.PubMed ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with more cardiovascular events

1.9×1.4× to 2.6×

Bigger than 9 in 10 for cardiovascular events

As reported

OR 1.89, 95% CI 1.35–2.63

Correlation · may be no link

No clear link with cardiovascular events

+30%−7% to +81%

Bigger than 6 in 10 for cardiovascular events

As reported

OR 1.30, 95% CI 0.93–1.81

Correlation, not cause

Went with fewer deaths

−35%−53% to −10%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.65, 95% CI 0.47–0.90 · the paper's word: All-cause mortality

+1 more in the walkthrough ↓

Four numbers in the abstract

the abstract, start to end

… with non-fatal cardiovascular events (OR 1.89 95% CI 1.35-2.63; p = 0.0002), but not with mortality (OR 1.30, 95% CI 0.93-1.81; p = 0.13).

… with a lower mortality rate (HR 0.65, 95% CI 0.47-0.90; p = 0.01) and a lower risk of death from malignancies (HR 0.25, 95% CI 0.08-0.83; p = 0.02).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
OR 1.891.35–2.63
Cardiovascular events
OR 1.300.93–1.81
All-cause mortality
HR 0.650.47–0.90
Adverse events & safety
HR 0.250.08–0.83
MetforminInsulinCardiovascular eventsAll-cause mortalityAdverse events & safety
1 / 3

43 papers cite it

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 21359582